Management of Lower Calyceal Stones with Double Collector System via Percutaneous Nephrolithotomy

Introduction to Percutaneous Nephrolithotomy

• The American Urological Association recommends percutaneous nephrolithotomy (PCNL) as the first-line treatment for lower calyceal stones >10 mm, with the supine position being safe and effective, offering specific advantages in patients with complex anatomy such as double collector systems 1, 2

Advantages of Supine Position in Complex Anatomy

• The supine position offers critical benefits for managing double collector systems, including simultaneous retrograde access, which is particularly useful in complex anatomy 2
• The supine and prone positions are equally safe according to current evidence, with comparable complication rates 2

Selection of Calyceal Access

• For lower calyceal stones with a double collector system, 10-50% of cases with complex anatomy require multiple percutaneous tracts to achieve complete clearance 1, 2
• Access through the upper pole typically provides optimal visualization of the complete collector system, but in double systems, it may be necessary to evaluate each system separately 3, 1

Surgical Technique

Positioning and Access

• Use ultrasonography for initial puncture, which reduces radiation exposure and has lower complication rates compared to fluoroscopy alone 2
• Dilate to 24-30 French with a balloon or coaxial dilators; single-step dilation can shorten operative time 3, 2

Fragmentation and Removal

• Perform routine flexible nephroscopy to access fragments that migrate to inaccessible areas, especially critical in double collector systems where fragments can migrate to the duplicate system 1, 2
• Use ultrasonic/neumatic lithotriptor for initial fragmentation with rigid nephroscopy, followed by holmium:YAG laser for flexible nephroscopy 3, 1
• Irrigation with normal saline solution is mandatory to prevent hemolysis and hyponatremia 1, 2

Expected Success Rates

• Primary clearance: 70.5-80.5% of patients achieve stone-free status or residual fragments <2 mm 3, 1
• Average procedures: 1.3 PCNL sessions are necessary for complete clearance in complex anatomy 3, 1

Postoperative Drainage Management

• Optional tubeless nephrostomy: after uncomplicated PCNL, nephrostomy tube placement is optional if there is no active bleeding and no anticipated need for percutaneous reaccess 1, 2
• Prolonged drainage: in complex cases with double collector systems, maintain nephrostomy for 24-48 hours to ensure adequate drainage 3

Critical Safety Considerations

Absolute Contraindications

• Untreated urinary infection: if purulent urine is found during the procedure, abort immediately and establish drainage with nephrostomy or ureteral stent, continuing broad-spectrum antibiotics 1
• Uncorrectable coagulopathy: it is an absolute contraindication for PCNL 4

Algorithm for Decision-Making for Multiple Accesses

Recovery Time

• Hospitalization: 1-5 days depending on complexity and need for secondary procedures 3, 1
• Return to normal activities: 1-2 weeks after removal of drainage tubes 3, 1

Common Errors to Avoid

• Not performing flexible nephroscopy: it is critical in complex anatomy to identify and remove small fragments that migrate to inaccessible areas 1, 2
• Using non-isotonic irrigation: always use normal saline solution to prevent electrolytic complications 1, 2
• Proceeding with active infection: always establish drainage and control infection before stone fragmentation 1

Predictive Value and Clinical Application of the Guy Stone Score in Percutaneous Nephrolithotomy

Predictive Value for Stone-Free Rates and Complication Risk

• The Society of Interventional Radiology establishes minimum technical success thresholds of 85% for complex stone disease, including staghorn calculi, which aligns with GSS Grade III-IV outcomes 5
• Blood transfusion requirement increases with higher GSS grades, with hemorrhage requiring transfusion occurring in 4-15% of PCNL cases overall, and septic shock occurs in 4% overall, 10% in pyonephrosis cases 5

Clinical Application and Technical Considerations

• For GSS Grade IV cases, consider combination therapy (PCNL + flexible nephroscopy), and counsel patients on 20-50% stone-free rate and high likelihood of staged procedures 6
• Flexible nephroscopy must be routinely performed to access stone fragments that migrate to areas inaccessible with rigid nephroscopy, particularly critical in Grade III-IV cases with complex anatomy 7
• Normal saline irrigation is mandatory to prevent hemolysis and electrolyte abnormalities 7

Evidence‑Based Outcomes and Complications in Post‑PCNL Drainage Management

Hemorrhagic Complications

• In patients undergoing percutaneous nephrolithotomy (PCNL), mild hematuria is observed in approximately 50 % of cases and is considered an expected postoperative finding. 8
• Clinically significant bleeding that necessitates blood transfusion occurs in about 15 % of PCNL procedures. 8
• Persistent postoperative bleeding should prompt arteriographic imaging to identify pseudo‑aneurysm, arteriovenous fistula, or extravasation, with definitive treatment by transcatheter embolization. 8
• Thrombocytopenia has been identified as a risk factor that increases the likelihood of postoperative bleeding after PCNL. 8

Infectious Complications

• Septic shock develops in roughly 4 % of all PCNL cases and in 10 % of cases complicated by pyonephrosis. 8
• Post‑procedural bacteremia is common when an infected urinary tract is drained during PCNL. 9
• Administration of pre‑procedural antibiotics is mandatory whenever urosepsis is suspected before performing PCNL. 9

Tube‑Related Complications

• Nephrostomy tubes placed after PCNL are prone to mechanical issues such as fracture, dislodgement, and occlusion. 8

Recovery Metrics

• Adoption of a tubeless approach (omitting the nephrostomy tube) shortens hospital stay from an average of 3 days to 1.5 days after uncomplicated PCNL. 8
• Analgesic requirements are reduced by approximately 67 % with the tubeless technique, decreasing opioid consumption from about 90 mg to 30 mg of pentazocine equivalents. 8